Capital Blue Cross is teaming up with the drug company to assist its members on discount medications.
Capital Blue Cross will become the first health plan in the nation to team up with Mark Cuban's Cost Plus Drugs, a drug company launched earlier this year, to help bring high-quality, lower-cost prescription drugs to its members as well as the communities it serves.
Cost Plus Drugs is providing the pharmaceutical industry transparent drug pricing and minimal markups and fees. The company charges consumers only 15% more than it pays to buy a drug from the manufacturer, along with a $3 per-prescription dispensing fee and shipping.
As a result, consumers can experience savings of up to 80% on some of the most commonly prescribed generic drugs.
Capital Blue Cross President and CEO Todd Shamash said the collaboration with the drug company will help bring lower-cost medications to members and nonmembers alike across our service area, "providing some much-needed relief to those struggling to pay for their vital – and sometimes life-saving – medications.”
“Our mission at Cost Plus Drugs is to ensure all consumers have access to the medications they need to be healthy – a goal Capital Blue Cross shares,” said Dr. Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “Working with a like-minded organization like Capital gives us more momentum to help people get the medications they need at costs they can afford.”
According to a September 2021 Gallup poll, 18 million Americans have been unable to afford at least one prescription medication for their household, and 1 in 10 Americans have skipped doses to save money. Both Capital Blue Cross and Cost Plus Drugs are dedicated to helping lower prescription drug costs to consumers so they don’t have to skip needed medications.
In 2023, Capital Blue Cross members will be able to use their insurance cards at Cost Plus Drugs, further increasing access and lowering out-of-pocket costs for Capital members and their families.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen